Retatrutide: Side Effects

Investigational Status Notice#

Retatrutide (LY3437943) is an investigational compound that has not been approved by the FDA or any other regulatory agency. All safety and side effect information presented here is derived from Phase 1 and Phase 2 clinical trial data involving a limited number of participants. The comprehensive safety profile of retatrutide is not yet established. Phase 3 clinical trials are ongoing and will provide more extensive safety data. This information is provided for educational and research purposes only.

Safety Profile Overview#

The safety and tolerability of retatrutide have been evaluated in Phase 1 and Phase 2 clinical trials. The Phase 2 obesity trial (Jastreboff et al., NEJM 2023; NCT04881760) enrolled 338 participants and provided the most comprehensive safety data available to date. The Phase 2 type 2 diabetes trial (Rosenstock et al., 2023) provided additional safety information in a diabetic population. As an investigational compound, the full safety profile of retatrutide remains under active characterization through the Phase 3 clinical program.

The overall tolerability pattern of retatrutide is broadly consistent with the established class effects of GLP-1 receptor agonists and the related dual GIP/GLP-1 agonist tirzepatide. Gastrointestinal adverse events were the most commonly reported side effects, were dose-dependent in frequency and severity, and were generally mitigated by gradual dose escalation protocols. The addition of glucagon receptor agonism to the GLP-1/GIP mechanism did not appear to introduce fundamentally novel adverse effect categories in the Phase 2 data, although longer-term and larger-scale studies are needed to confirm this observation.

Documented Adverse Effects from Phase 2 Trials#

Gastrointestinal Side Effects#

Gastrointestinal (GI) adverse events were the most frequently reported side effects in Phase 2 trials, consistent with the known pharmacology of GLP-1 receptor agonism. The GLP-1 receptor is expressed throughout the gastrointestinal tract, and its activation delays gastric emptying, reduces gastric acid secretion, and modulates gut motility. These effects, while contributing to the appetite-suppressive and glycemic benefits of the drug, also underlie the predominant GI side effect profile.

Nausea was the most commonly reported adverse event, occurring in approximately 25% of participants at the higher dose levels (8 mg and 12 mg). Nausea was generally rated as mild to moderate in severity, was most pronounced during the initial dose escalation period, and typically improved with continued treatment. The dose-dependent nature of nausea was evident across the dose groups, with lower doses (0.5 mg, 1 mg) producing substantially less nausea than the higher therapeutic doses.

Diarrhea was reported in approximately 20% of participants at higher doses. Episodes were generally mild and self-limiting, resolving without the need for treatment discontinuation in most cases. Diarrhea is a recognized class effect of GLP-1 receptor agonists and is attributed to altered gut motility and increased intestinal secretion.

Vomiting occurred in approximately 15% of participants, with higher frequency at the 8 mg and 12 mg dose levels. Vomiting was generally moderate in severity and was more common during the initial weeks of treatment or during dose escalation steps. In the Phase 2 trials, gradual dose escalation over 12-24 weeks was employed specifically to improve tolerability, and this strategy appeared to reduce the incidence and severity of vomiting compared to more rapid escalation schedules.

Decreased appetite was reported commonly and is considered a pharmacologically expected effect rather than a pure adverse event. The appetite-suppressive effects of GLP-1 receptor agonism are central to the weight loss mechanism of retatrutide. However, excessive appetite reduction leading to inadequate caloric intake was monitored, and participants were counseled to maintain adequate nutrition.

Constipation was reported in a notable proportion of participants and is attributed to the delayed gastric emptying and reduced gut motility caused by GLP-1 receptor activation. This adverse effect is well-characterized across the GLP-1 agonist class and is typically manageable with dietary measures and over-the-counter treatments.

Dyspepsia (indigestion, upper abdominal discomfort) was less commonly reported but occurred in some participants across dose groups. This symptom was generally mild and did not lead to treatment discontinuation.

Dose-Dependent Nature of GI Adverse Events#

A clear dose-response relationship was observed for GI adverse events in the Phase 2 program. Higher doses (8 mg and 12 mg) were associated with greater frequency and intensity of GI symptoms compared to lower doses (0.5 mg, 1 mg, 4 mg). This observation informed the dose escalation strategy, wherein participants initiated treatment at 0.5 mg weekly and gradually escalated to their target dose over 12 to 24 weeks. This gradual titration approach is intended to allow physiological adaptation to the GI effects of incretin receptor agonism and has been established as standard practice in the class.

The escalation-based tolerability strategy appeared effective: most GI adverse events were transient, occurring primarily during the escalation period, and diminished in frequency and severity once a stable dose was reached. However, a proportion of participants experienced persistent GI symptoms at the higher doses, and this remains an important consideration for the Phase 3 program.

Injection Site Reactions#

Injection site reactions, including localized redness, swelling, pruritus, and mild pain at the subcutaneous injection site, were reported in a common proportion of participants. These reactions were uniformly mild, transient, and did not lead to treatment discontinuation. Injection site reactions are a recognized class effect of all subcutaneously administered peptide therapies and are managed through injection site rotation and proper technique.

Discontinuation Due to Adverse Events#

In the Phase 2 obesity trial, the overall discontinuation rate due to adverse events was relatively low across dose groups, although it was higher at the 12 mg dose. Most discontinuations were attributable to GI adverse events (nausea, vomiting, or diarrhea). The Phase 3 program, with its larger participant numbers and potentially refined dose escalation protocols, will provide more definitive data on treatment discontinuation rates and their causes.

Anticipated Contraindications#

As an investigational compound without regulatory approval, retatrutide does not have formally established contraindications. However, based on the known pharmacology of the GLP-1 receptor agonist class and regulatory precedent from approved drugs in this class (semaglutide, tirzepatide, liraglutide), the following contraindications are anticipated:

Personal or family history of medullary thyroid carcinoma (MTC): All approved GLP-1 receptor agonists carry a boxed warning regarding the risk of thyroid C-cell tumors. In rodent studies, GLP-1 receptor agonists have caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas). While the relevance of these rodent findings to humans is uncertain (humans have far fewer thyroid C-cell GLP-1 receptors than rodents), regulatory agencies have required this warning as a precautionary measure. Retatrutide would be expected to carry a similar warning given its GLP-1 receptor agonist activity.

Multiple endocrine neoplasia syndrome type 2 (MEN2): Patients with MEN2 are predisposed to medullary thyroid carcinoma, and GLP-1 receptor agonists are contraindicated in this population as a precautionary extension of the MTC concern.

Pregnancy: Weight loss during pregnancy poses risks to the fetus. No reproductive toxicology data for retatrutide have been published. Based on class precedent (semaglutide and tirzepatide are contraindicated or not recommended in pregnancy), retatrutide would be expected to carry a similar warning. Women of reproductive potential would be advised to use effective contraception during treatment and for a washout period following discontinuation.

Known hypersensitivity: Hypersensitivity to the active substance or any excipient would be a standard contraindication, consistent with all approved medications.

Drug Interactions#

No formal drug-drug interaction studies for retatrutide have been published. The following potential interactions are inferred from the pharmacology of retatrutide and the established interaction profiles of approved GLP-1 receptor agonists:

Insulin and insulin secretagogues (sulfonylureas): Retatrutide enhances glucose-dependent insulin secretion through both GLP-1 and GIP receptor agonism. When combined with exogenous insulin or sulfonylureas, the risk of hypoglycemia may be increased. In the Phase 2 diabetes trial, participants on background insulin or sulfonylureas required dose adjustments. This interaction is well-characterized across the GLP-1 agonist class.

Oral medications affected by gastric emptying: GLP-1 receptor agonists delay gastric emptying, which can alter the absorption kinetics of concomitantly administered oral medications. Medications with narrow therapeutic indices or those requiring rapid absorption for efficacy (such as oral contraceptives, antibiotics, and warfarin) may be affected. While the clinical significance of this interaction has generally been modest for approved GLP-1 agonists, patients should be counseled about potential absorption effects. The triple-agonist mechanism of retatrutide may produce different gastric emptying kinetics than single or dual agonists, but this has not been specifically studied.

Warfarin and anticoagulants: Altered absorption of warfarin due to delayed gastric emptying could affect INR control. More frequent INR monitoring may be warranted during initiation and dose adjustment of retatrutide in patients on warfarin, consistent with class recommendations.

Glucagon-Specific Safety Considerations#

The glucagon receptor agonist component of retatrutide introduces pharmacological effects not present in approved GLP-1 or dual GIP/GLP-1 agonists. Several theoretical safety considerations arise from this novel mechanism:

Hyperglycemia risk: Glucagon is the primary counter-regulatory hormone that stimulates hepatic glucose production. Glucagon receptor agonism in isolation would be expected to raise blood glucose levels. In retatrutide, this effect is counterbalanced by the simultaneous GLP-1 and GIP receptor activation, which enhance insulin secretion and promote glucose disposal. In Phase 2 trials, the net glycemic effect was favorable (HbA1c reduction), suggesting that the insulin-stimulating components predominate. However, in certain clinical contexts (e.g., patients with markedly impaired beta-cell function, concurrent illness, or fasting states), the glucagon component could theoretically contribute to glycemic excursions. This risk warrants monitoring in Phase 3 studies.

Heart rate and cardiovascular effects: Glucagon has chronotropic effects that can increase heart rate. Small increases in heart rate have been observed with GLP-1 receptor agonists generally, and the addition of glucagon receptor agonism could potentially amplify this effect. Heart rate monitoring in Phase 2 trials did not reveal clinically concerning changes, but longer-term cardiovascular safety assessment is needed.

Hepatic effects: Glucagon receptor agonism stimulates hepatic lipid oxidation, which is a potential therapeutic benefit for MASLD but could theoretically affect hepatic function parameters. Liver enzyme monitoring in Phase 2 trials did not reveal hepatotoxicity signals, but ongoing surveillance is warranted.

Adverse Event Summary Table#

Evidence Gaps and Limitations#

The safety profile of retatrutide is subject to several important limitations that must be considered:

• Limited sample size: Phase 2 trials enrolled approximately 338 participants (obesity trial) and a similar number for the diabetes indication. This sample size is insufficient to detect rare adverse events (those occurring in fewer than 1 in 100-500 patients).

• Limited treatment duration: The maximum treatment duration in Phase 2 was 48 weeks. Long-term safety beyond one year is entirely unknown.

• No post-marketing data: Unlike approved drugs such as semaglutide and tirzepatide, retatrutide has no post-marketing safety data from real-world clinical use.

• Thyroid C-cell tumor risk: Rodent thyroid C-cell tumor data specific to retatrutide have not been published. The expected boxed warning is based on class precedent.

• Cardiovascular safety: No dedicated cardiovascular outcomes trial has been conducted. Long-term cardiovascular safety, including effects on MACE, heart failure, and arrhythmia, is unknown.

• Pancreatitis risk: GLP-1 receptor agonists have been associated with rare cases of acute pancreatitis. Whether retatrutide carries a similar or different pancreatitis risk is not established.

• Gallbladder events: Cholelithiasis and cholecystitis have been reported with rapid weight loss from GLP-1 agonists. The substantial weight loss achieved with retatrutide may carry a similar risk.

• Special populations: Safety in pregnant or lactating women, pediatric patients, elderly patients with multiple comorbidities, and patients with severe renal or hepatic impairment has not been studied.

Phase 3 clinical trials currently underway are expected to provide substantially more comprehensive safety data across larger and more diverse patient populations. Until these data are available, the safety profile of retatrutide should be considered incompletely characterized, and the compound remains available only through clinical trial participation.

Related Reading#

• Retatrutide overview and research guide
• Retatrutide dosing protocols
• Retatrutide risks and legal status